Exhale

The official blog of the Lung Institute.

Late Stage Lung Disease Sufferers Now Exploring Cellular Therapies as Alternative to Lung Transplantation

30 Oct 2013
| Under Press | Posted by
| 0 Comments

The Lung Institute Educates the Public on the Restorative Nature of Regenerative Medicine in Support of Healthy Lung Month

Tampa, Fla. (October 30, 2013) – Regenerative medicine is the latest medical technology for the promotion of healing of lung tissue affected by lung disease. The Lung Institute’s physicians have harnessed this advancement in modern medicine to bring patients with conditions like chronic obstructive pulmonary disease (COPD), pulmonary fibrosischronic bronchitis and emphysema an innovative treatment choice that betters their quality of life and helps them to breathe easier.

Often, many of these patients have been told that lung transplantation is their only option, and as a result many are turning to advanced treatments such as pulmonary cellular therapies to enhance lung function and promote healing. Here’s some information about how Cellular Therapies as Alternative to Lung Transplantation could be beneficial for people with chronic lung diseases.

How do Cells Help Damaged Lung Tissue?

The Lung Institute utilizes autologous cells, meaning those derived from the patient’s own blood, for treatment.

Both cellular therapies and lung transplantation have been proven, in many cases, to improve quality of life. However, lung transplantation is an invasive inpatient surgery that has far riskier complications and a longer recovery time.

About Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Tampa, Fla., Nashville, Tenn., Scottsdale, Ariz., Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call 888-745-6697.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.